IVVD

Invivyd, Inc.

1.93 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Invivyd, Inc. stock is down -7.21% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 May’s closed higher than April. 100% of analysts rate it a buy.

About Invivyd, Inc.

Adagio Therapeutics focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease.

  • HC Wainwright & Co.
    Fri May 24, 12:49
    buy
    confirm
  • HC Wainwright & Co.
    Tue May 14, 12:33
    buy
    confirm